Information updates

Recent tick allergy publication supports ASCIA recommendations

7 May 2019

tick publicationA study titled “Tick killing in situ before removal to prevent allergic and anaphylactic reactions in humans: a cross-sectional study” has recently been published.  It is available open access from the Asia Pacific Allergy journal   

Results from this published study support the use of ether containing sprays to kill ticks.  These sprays are approved by the TGA for use on human skin in Australia.  The study results also support the following ASCIA recommendations.

To prevent allergic reactions to ticks do NOT forcibly remove the tick. Disturbing the tick may cause the tick to inject more allergen-containing saliva. The options are to:

  • Leave tick in place and seek medical assistance; OR
  • Freeze tick (using a product that rapidly freezes and kills the tick) and allow to drop off.

The ASCIA document on tick allergy is available at    

Another recent publication reports on a second tick species that has been associated with mammalian meat allergy in Australia.   

Continue reading

UK inquest into fatal anaphylaxis

6 May 2019

It is with great sadness that we read about the recent UK inquest into a case of fatal anaphylaxis of a 13 year old school student, Karanbir Cheema, who had multiple food allergies.  

The Coroner's Court heard that whilst there were other cases of children having severe allergic reactions through skin contact, none of these incidents had been fatal. The inquest was told that Karanbir had eczema and he scratched at his neck after contact with cheese, with blood visible following the incident. Further scratching and degrading of the skin barrier could have led to increased contact with the cow’s milk protein.  His adrenaline (epinephrine) autoinjector was 11 months out of date and this was the only adrenaline administered before he went into cardiac arrest.

Continue reading

Novalac Allergy Infant Formula Supply Update

30 April 2019

Bayer Australia Ltd (Bayer) has advised ASCIA that Novalac Allergy formula is currently out of stock and ongoing stock shortages will continue over the coming months.  Please note that other Novalac products are unsuitable for infants diagnosed with cow’s milk protein allergy (CMPA).  Information on alternative formulas for infants with CMPA is on the ASCIA website: 

GPs, allergy and paediatric specialists can contact the Bayer Medical Information Team on behalf of patients to discuss compassionate/critical medical cases on 1800 008 757 or by emailing This email address is being protected from spambots. You need JavaScript enabled to view it.

Bayer continues to work as a priority with the global manufacturing partner to increase supply of Novalac Allergy and an update on stock availability will be provided in June.

pdfNovalac Allergy Infant Formula Supply Update April 2019

Continue reading

National Allergy Strategy funding and World Allergy Week 2019

5 April 2019

ASCIA greatly appreciates the funding that has been provided by the Australian Government to implement National Allergy Strategy projects. This includes funding that was announced by the Health Minister today, Friday 5 April 2019, which will allow the continuation of these important projects.

World Allergy Week 2019

Further long-term support is required to implement larger scale projects. As part of World Allergy Week (7-13 April 2019), we encourage anyone who is affected by allergy to support the National Allergy Strategy's $20 million election plea. This plea has been made to all major political parties and you can show your support by signing a petition and sharing it with family and friends.

Continue reading

International Women's Day

8 March 2019

International Womens Day ASCIA PresidentsToday, ASCIA is proud to have our three past Presidents and the current President Elect, working together at the inaugural National Immunodeficiency Strategy meeting.

Prof Connie Katelaris, Prof Jo Douglass, Dr Melanie Wong and Prof Michaela Lucas have all made substantial contributions to allergy, clinical immunology and ASCIA. 

An example of their ongoing and outstanding commitment, is their involvement in the National Immunodeficiency Strategy meeting, a ground breaking initiative hosted by ASCIA.

Catalyst allergy program

13 February 2019

If you missed watching the Catalyst allergy program on ABC TV last night (12 February 2019),  you can watch it on ABC iview  

Several ASCIA members were involved in the program, including Prof Connie Katelaris, Prof Dianne Campbell, Dr Preeti Joshi, Carolina Valerio, Rebecca Sertori and Prof Janet Davies.

The Catalyst allergy program highlights the high prevalence, wide range and seriousness of allergic conditions.  These include food allergy, anaphylaxis, allergic rhinitis, asthma, eczema and cold urticaria (hives). 

Skin testing, food allergen challenge testing, the need to seek professional help from a specialist and examples of current research were featured in the program.  It was also explained why more research is required.

How can you help support research?

By making a tax deductable donation to AIFA, this will enable AIFA to fund more allergy/immunology research.

Expressions of interest (EOI) for AIFA 2019 grants for allergy/immunology research ($120,000 in total) are due by the closing date of 15 April 2019. 


AusPollen post-season questionnaire 2018/2019

12 February 2019

Do you have hay fever Is your asthma made worse by allergens in the air?

Local AusPollen Apps provide daily levels of pollen in the air during the grass pollen season. 

To help the AusPollen partnership project team evaluate the Apps and how they can improve this service, please complete a short questionnaire.

Pollen counting will resume next spring.  You can access the service on the website or via itunes or Google Play Apps, twitter or facebook. 

If you would like to know more about the AusPollen project please contact Prof Janet Davies, Queensland University of Technology, This email address is being protected from spambots. You need JavaScript enabled to view it.

Continue reading

Happy New Year to ASCIA members and supporters

7 January 2019

As we commence 2019, we take this opportunity to wish you a happy new year and thank you for your support, which has helped ASCIA achieve so much in 2018.

For a summary of ASCIA highlights from 2018 go to

In 2019 we are looking forward to celebrating ASCIA’s 30th anniversary, at the ASCIA Annual Conference in Perth Western Australia, from 4-6 September 2019.

For preliminary information go to

The ASCIA Annual Conference is one of the following six priorities for ASCIA in 2019:

1. ASCIA Annual Conference

2. ASCIA Education Project 

3. National Immunodeficiency Strategy

4. AIFA Research Grant Program 

5. National Allergy Strategy 

6. ASCIA Communications, Advocacy and Collaborations 

To read more about ASCIA priorities, projects and collaborations planned for 2019 go to

Continue reading

More Articles ...

Mod ASCIA Member
Donate to AIFA
go to NAS website

ASCIA is the peak professional body of clinical immunology and allergy in Australia and New Zealand
ASCIA promotes and advances the study and knowledge of allergy and other immune diseases

Quick Links


ASCIA is a registered trademark of the Australasian Society of Clinical Immunology and Allergy. All content is subject to copyright for the Australasian Society of Clinical Immunology and Allergy. Read more...

The content for the website is developed and approved by ASCIA Committee and ASCIA Working Party Members. Read more...

Disclaimer I Privacy

The ASCIA website is intended for use by ASCIA members, health professionals and the general public. The content provided is for education, communication and information purposes only and is not intended to replace or constitute medical advice or treatments. Read more...

ASCIA respects your privacy. Read our privacy policy here...

Sponsors | Advertising

ASCIA does not endorse products from sponsoring organisations, nor is it influenced by sponsoring organisations with regard to the content of education programs and websites. 

The ASCIA website does not accept advertising. Any link to a third-party website does not imply any endorsement by ASCIA.


This website is certified by Health On the Net Foundation. Click to verify.This site complies with the HONcode standard for trustworthy health information.Verify here.